<DOC>
	<DOCNO>NCT00875173</DOCNO>
	<brief_summary>Background : Chagasic myocardiopathy cause protozoa Trypanosoma cruzi principal cause cardiac death Latin America . Without trypanocidal therapeutic intervention , infected subject pass indeterminate cardiac form heart dysfunction . Our group study role effect supplementation essential micronutrient selenium ( Se ) T. cruzi infection , investigator verify : 1. low Se level relate severity myocardiopathy chagasic patient 2. adequate Se diet essential mouse survival acute phase experimental T. cruzi infection 3 . Se supplementation prevent myocardial lesion acute phase mouse . From finding consider Se supplementation able prevent Keshan cardiopathy , revert electrocardiographic echocardiographic alteration patient nourished parenteral route , reduce re-infarction cardiac death acute myocardial infarction ; investigator purpose investigate Se treatment via oral route , able impair progress heart dysfunction chagasic patient express study progression rate comparison mean ventricular ejection fraction . Methods : The Selenium treatment Chagasic Cardiopathy ( STCC ) trial double-blind , placebo control , randomize 130 chagasic patient chronic phase follow inclusion criterion ( ) alter ECHO ( LVEF 0,35 % 45 % ) , ( b ) age 20 65 year , ( c ) randomly divide two group : Placebo ( n=65 ) Se ( n=65 ) . Patients Se group intake diary 100 Âµg Se sodium selenite 12 month . The primary endpoint reduction 50 % progression rate heart dysfunction , secondary endpoint partial total reversion electrocardiography alteration . Conclusion : This trial recently approve Brazilian Research Ethics Committee conduct accordance principle human experimentation . If investigator confirm benefit Se treatment , strategy utilization micronutrient adequate concentration treatment diary diet revolutionize therapeutic chagasic myocardiopathy .</brief_summary>
	<brief_title>Selenium Treatment Chagasic Cardiopathy ( STCC )</brief_title>
	<detailed_description>Several induce cardiomyopathy , Mycoplasma pneumonia-induced myocarditis , heart damage investigation show positive effect Se experimental model : cardiotoxicity induce chemotherapics , ischemic cardiopathy , CVB3 LP-BM5 ( murine AIDS , retrovirus ) -in reperfused heart , chagasic cardiopathy . In addition , beneficial effect Se supplementation report patient myocardial infarct , Keshan disease , cardiac dysfunction HPN . Our group investigate role Se effect infection T. cruzi . By evaluate plasma Se level 170 chagasic patient , discover frequency subject Se level low normal significantly high severe cardiopathy . Moreover , pioneer research , find positive correlation Se level LVEF , indicate normal Se level pave way efficient cardiac function . Later , investigate nutritional deficiency trace element interfere development cardiopathy susceptibility experimental T. cruzi infection . In study , find 100 % mortality Se deficient mouse , selenium adequate group 20 % male female die even 40 dpi . In addition , parasitemia level infect mice alter Se deficiency , suggest high susceptibility acute phase due parasite load . We later investigate Se treatment could minimize course T. cruzi infection myocarditis mouse . We verify concentration 4 ppm Se alter resistance infection able prevent increase CK-MB level infect mouse , indicate Se help protect heart inflammatory damage drive T. cruzi infection . Currently , experimental clinical trial concern Se supplementation perform ; however , date , trial regard use micronutrient treatment protect cardiac function chagasic patient cardiopathy . The present clinical trial aim study effect Se intervention progression rate cardiopathy patient mild moderate HD ( LVEF 35 % 45 % ) order validate new strategy treatment . The HD express progression rate comparison mean LVEF . In context test hypothesis Se treatment able interfere progression cardiac dysfunction chronic chagasic patient . We expect impediment progression ventricular dysfunction patient mild HD , improvement cardiac function patient moderate HD group patient receive Se therapy . This first clinical trial concern specific group cardiac chagasic patient mild moderate HD .</detailed_description>
	<mesh_term>Chagas Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>alter ECHO ( LVEF 0,35 % 45 % ) age 20 65 year patient &gt; 65 year age smoke habit , patient nonchagasic cardiopathy , live close mineral deposit , metal industry place radioactive exposition , vegetarian depressive psychological profile pregnant lactating period present presented cancer diabetes . patient exclude take anticonvulsive medicine ( Clozapine , Valproic Acid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Selenium</keyword>
	<keyword>Chagas disease</keyword>
	<keyword>Chagasic cardiopathy</keyword>
</DOC>